OakChart

X4 Pharmaceuticals Inc

XFORHealthcare·Biotechnology·USA·Small·NASD·Nov 11 • 3:59 PM ET

3.23-0.01 (-0.46%)
2026-11-12 03:39 CET
Market cap
329.83 USD m
Revenue, TTM
16.96 USD m
Net income, TTM
-80.52 USD m
Free cash flow, TTM
- USD m
EPS diluted, TTM
-0.66
P/E
-
Compare

Price

XFOR against its 20, 50 and 200-day averages
2050200beat
3.004.005.2M10.5MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26XFORclose 3.2320-day 3.1450-day 3.19200-day 3.783.2352w high52w low

33.1% under the 52-week high of 4.83 on 10 Mar 2026. 52-week low 2.43 on 14 Oct 2026. Last 15 sessions, 20.6% high to low

Volume 0.92× normal · the line is the 50-bar volume average

Profile

XFOR
52-week range, 33% of the way up
2.434.83

X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. It is focused on mavorixafor which is being marketed in the U.S. under the trade name xolremdi. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan in 2010 and is headquartered in Boston, MA.

IndexRUT
Employees45
IPONov 16, 2017
Beta0.47
ATR, 14d0.24
Rel volume0.92
Short float10.31%
Insider own24.29%
Inst own78.32%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap329.83M
Enterprise Value218.65M
Income-80.52M
Sales16.96M
Book/sh1.38
Cash/sh1.84
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees45
IPONov 16, 2017

Ratios

P/E-
Forward P/E-
PEG-
P/S19.45
P/B2.35
P/C1.75
P/FCF-
EV/EBITDA-
EV/Sales12.89
Quick Ratio12.86
Current Ratio13.22
Debt/Eq0.56
LT Debt/Eq0.55
Option/ShortYes / Yes

Earnings

EPS (ttm)-0.66
EPS next Y-0.76
EPS next Q-0.19
EPS this Y66.52%
EPS next Y-21.41%
EPS next 5Y23.26%
EPS past 3/5Y65.48% 54.19%
Sales past 3/5Y- 63.56%
EPS Y/Y TTM93.36%
Sales Y/Y TTM-50.08%
EPS Q/Q76.84%
Sales Q/Q63.12%
EarningsNov 04 BMO
EPS/Sales Surpr.5.88% 8.32%

Ownership

Insider Own24.29%
Insider Trans-0.42%
Inst Own78.32%
Inst Trans2.89%
ROA-40.73%
ROE-80.32%
ROIC-37.30%
Gross Margin80.90%
Oper. Margin-473.95%
Profit Margin-474.74%
SMA202.83%
SMA501.35%
SMA200-14.60%
Trades-

Technical

Shs Outstand100.90M
Shs Float77.31M
Short Float10.31%
Short Ratio9.41
Short Interest7.97M
52W High4.83 -33.13%
52W Low2.43 32.92%
Volatility7.46% 8.08%
ATR (14)0.24
RSI (14)52.50
Beta0.47
Rel Volume0.92
Avg Volume847.68K
Volume776,242

Performance

Perf Week-0.31%
Perf Month24.23%
Perf Quarter-24.71%
Perf Half Y-23.64%
Perf YTD-19.25%
Perf Year-8.50%
Perf 3Y-85.65%
Perf 5Y-97.74%
Perf 10Y-
Recom1.00
Target Price11.60
Prev Close3.24
Price3.23
Change %-0.46%

Analyst ratings

latest 10 of 14
DateActionAnalystRating changeTargetImplied
Jul 10, 2026InitiatedWWells FargoOverweight$11+240.6%
Jun 02, 2026InitiatedLLeerink PartnersOutperform$12+271.5%
Mar 09, 2026InitiatedGGuggenheimBuy$12+271.5%
Dec 05, 2025ResumedSStifelBuy$10+209.6%
Dec 12, 2023DowngradeRB. Riley SecuritiesBuy → Neutral$3 → $1-69.0%
Aug 30, 2023ResumedRB. Riley SecuritiesBuy$3-7.1%
Dec 22, 2022InitiatedCCantor FitzgeraldOverweight$3-7.1%
Dec 12, 2022InitiatedPPiper SandlerOverweight$3-7.1%
Dec 23, 2019InitiatedOOppenheimerOutperform$20+519.2%
Dec 18, 2019InitiatedRROTH CapitalBuy$20+519.2%

Peers

Mkt cap
TickerCompanyMkt cap
PHARPharming Group NV ADR948.45M
ZVRAZevra Therapeutics Inc705.13M
ADMAAdma Biologics Inc2.93B
RIGLRigel Pharmaceuticals838.31M
RAREUltragenyx Pharmaceutical Inc1.70B
PLXProtalix BioTherapeutics Inc252.18M
RLYBRallybio Corp85.07M
MIRMMirum Pharmaceuticals Inc6.18B
KRYSKrystal Biotech Inc9.15B
CTXRCitius Pharmaceuticals Inc13.20M

Insider trading

10 filings
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Craig Adam RExecutive ChairmanOct 16 '26Buy2.584,60011,884333,251Oct 19 04:06 PM
KIRSKE DAVIDChief Financial OfficerOct 01 '26Sale2.8611,76733,658155,983Oct 05 04:03 PM
David KirskeOfficerOct 01 '26Proposed Sale2.8611,76733,658Oct 01 08:05 PM
Volpone JohnPresidentAug 12 '26Sale4.4424,576109,228265,305Aug 13 04:13 PM
Craig Adam RExecutive ChairmanAug 12 '26Sale4.4447,436210,829328,651Aug 13 04:10 PM
John VolponeOfficerAug 12 '26Proposed Sale4.5524,576111,944Aug 13 04:00 PM
Adam CraigExecutive ChaimanAug 12 '26Proposed Sale4.5647,436216,071Aug 13 03:59 PM
KIRSKE DAVIDChief Financial OfficerJun 30 '26Sale4.268,54336,428167,750Jul 01 04:23 PM
KIRSKE DAVIDChief Financial OfficerMay 12 '26Sale4.2916,96172,820176,293May 13 04:02 PM
David KirskeOfficerMay 12 '26Proposed Sale4.2916,96172,820May 12 06:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWMiShares Russell 2000 Index FundAUM: 77.38B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
SBIOALPS Medical Breakthroughs ETFAUM: 192.65M
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
VTWVVanguard Russell 2000 Value Index ETFAUM: 1.29B
PRFZInvesco RAFI US 1500 Small-Mid ETFAUM: 2.66B

News

latest 14 of 200
  • X4 Pharmaceuticals: Q3 Earnings Snapshot (Associated Press) -5.25%
  • X4 Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
  • X4 Pharmaceuticals to Participate in Guggenheim, Stifel, and Jefferies Conferences in November 2026 (GlobeNewswire) -5.37%
  • 4 Biotech Stocks Seeing Unusual Options Volume Today (Schaeffer's Research)
  • X4 Pharmaceuticals Highlights Clinical Progress and Market Opportunity for Mavorixafor in Primary Chronic Neutropenia During Virtual Investor Day (GlobeNewswire)
  • X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders (GlobeNewswire)
  • X4 Pharmaceuticals Secures Up to $150 Million in New Debt Financing From K2 HealthVentures (InvestorsHub)
  • X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures (GlobeNewswire)
  • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • X4 Pharmaceuticals to Participate in a Fireside Chat at the 2026 Wells Fargo Healthcare Conference (GlobeNewswire)
  • X4 Pharmaceuticals Announces Positive Outcome from FDA Type C Meeting (GlobeNewswire) -13.24%
  • X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
  • X4 Pharmaceuticals: Q2 Earnings Snapshot (Associated Press) +11.27%
  • X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-04-0.160-0.170-0.1402.772.565
2026Q22026-08-06-0.130-0.176-0.1108.812.425
2026Q12026-05-06-0.160-0.200-0.1602.713.203
2025Q42026-03-17-0.220-0.273-0.2162.571.734
2025Q32025-11-05-0.690-0.505-0.6891.771.904
2025Q22025-07-31-3.368-3.938-3.4721.981.625
2025Q12025-05-010.040-3.5500.04128.8111.586
2024Q42025-03-25-6.000-5.280-5.8871.431.065
2024Q32024-11-13-5.400-5.142-5.4810.561.697
2024Q22024-08-0813.500-0.21313.5710.5815.277
2024Q12024-05-07-7.800-4.629-7.7650.000.007
2023Q42024-03-21-3.000-4.371-2.8870.000.007
2023Q32023-11-09-0.300-4.467-0.3510.000.009
2023Q22023-08-10-9.900-4.866-9.9050.000.009
2023Q12023-05-04-4.800-6.375-4.9370.000.008
2022Q42023-03-21-8.700-8.100-8.6650.000.008

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-138.9-133.76-138.940.000.00
2020FY-92.700-93.306-92.8393.003.00
2021FY-119.7-90.000-119.580.000.00
2022FY-45.600-42.450-45.5310.000.00
2023FY-17.100-18.300-17.0690.000.00
2024FY-5.700-3.900-5.5882.562.20
2025FY-1.870-2.038-1.54035.1134.24
2026FY--0.626--17.28
2027FY--0.760--12.40
2028FY--0.845--36.35
2029FY--0.135--211.35
2030FY-1.193--523.53

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-055302.762.503.30
2026Q4S2026-11-045302.762.503.30
2026Q4S2026-11-035102.481.503.00
2026Q4S2026-10-215002.281.502.90
2026Q4S2026-08-075102.281.502.90
2026Q4S2026-07-205002.241.502.70
2026Q4S2026-07-085202.241.502.70
2026Q4S2026-06-014202.301.502.70
2026Q4S2026-05-063202.171.502.50
2026Q4S2026-03-173001.671.501.90
2026Q4S2026-03-063002.751.504.84
2026Q4S2026-02-052003.171.504.84
2026Q4S2026-01-203002.911.504.84
2026Q4S2025-12-043012.911.504.84

Estimate history

EPS, annual-17767.912-14238.072-138.939-92.839-119.584-45.531-17.069-5.588-1.873-0.6642
Period201720182019202020212022202320242025TTM
EPS, quarterly-5.481-5.8870.041-3.472-0.689-0.216-0.16-0.128-0.16
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual00030002.55735.11316.96
Period201720182019202020212022202320242025TTM
Sales, quarterly0.561.43428.8071.9731.7652.5682.7088.8062.879
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual0.0130.0020.5380.5440.9384.0565.5815.69890.907100.904
Period201720182019202020212022202320242025MRQ
Shares, quarterly5.6175.6985.7897.9625.14690.90794.3296.115100.904
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue16.9635.112.560.000.000.003.000.000.00
Cost of Goods Sold Incl. D&A3.246.261.092.001.991.891.230.670.10
Gross Profit13.7228.861.46-2.00-1.99-1.891.77-0.67-0.10
Selling, General and Administrative Excl. Other94.11115.74142.87105.5386.0873.4661.6446.1328.98
Research and Development62.2472.2281.3570.0259.0648.7640.7030.1620.35
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-80.39-86.88-141.40-107.52-88.08-75.35-59.87-46.80-29.09
Interest Expense8.688.888.775.783.993.642.692.150.72
Unusual Expense-0.93-12.78-1.93-7.07-1.7010.120.605.573.72
Net Income Before Taxes-80.52-79.16-37.14-101.09-93.84-88.68-61.98-52.81-33.28
Income Taxes0.010.040.310.080.030.020.150.000.00
Consolidated Net Income-80.52-79.20-37.45-101.17-93.87-88.70-62.13-52.81-33.28
Net Income From Continuing Operations-80.52-79.20-37.45-101.17-93.87-88.70-62.13-52.81-33.28
Net Income-80.52-79.20-37.45-101.17-96.41-102.64-62.13-53.40-36.31
EPS (Recurring)-0.64-2.08-5.79-17.90-46.09-111.33-92.21-128.79-13,217.99
EPS (Basic, Before Extraordinaries)-0.66-1.87-5.59-17.07-45.53-119.58-92.84-138.94-14,238.07
EPS (Diluted)-0.66-1.87-5.59-17.07-45.53-119.58-92.84-138.94-14,238.07
EBITDA-78.54-85.61-140.60-105.53-86.08-73.46-58.64-46.13-28.98
Non-Operating Income (Expense)7.623.82111.105.14-3.470.441.181.710.24
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense9.893.406.486.864.114.513.962.050.76
Price To Sales Ratio21.634.8257.68---43.03-9.48
Gross Margin80.9082.1857.25---59.00--
Operating Margin-473.95-247.44-5,529.96----1,995.80--
Net Margin-474.74-225.55-1,464.61----2,071.03--
Shares Outstanding100.9090.915.705.584.060.940.540.540.00
Market Capitalization329.83329.83125.41138.1168.2564.41104.85172.585.63

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue2.888.812.712.571.761.9728.811.43
Cost of Goods Sold Incl. D&A0.571.650.630.390.370.495.000.39
Gross Profit2.317.152.072.181.391.4823.801.05
Selling, General and Administrative Excl. Other22.3023.5522.3825.8828.9027.7133.2436.76
Research and Development13.2915.0415.4118.5017.3118.1818.2221.62
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-19.99-16.39-20.31-23.70-27.51-26.23-9.44-35.72
Interest Expense2.192.162.132.192.262.232.202.30
Unusual Expense-0.34-0.53-0.080.020.68-2.64-10.832.67
Net Income Before Taxes-20.20-16.16-20.24-23.93-29.84-25.700.32-39.56
Income Taxes0.000.000.000.00-0.030.040.030.26
Consolidated Net Income-20.20-16.16-20.24-23.93-29.82-25.740.28-39.82
Net Income From Continuing Operations-20.20-16.16-20.24-23.93-29.82-25.740.28-39.82
Net Income-20.20-16.16-20.24-23.93-29.82-25.740.28-39.82
EPS (Recurring)-0.16-0.13-0.16-0.22-0.68-3.72-1.06-5.61
EPS (Basic, Before Extraordinaries)-0.16-0.13-0.16-0.22-0.69-3.470.04-5.89
EPS (Diluted)-0.16-0.13-0.16-0.22-0.69-3.470.04-5.89
EBITDA-19.64-15.36-20.07-23.48-27.29-25.86-8.95-35.44
Non-Operating Income (Expense)1.651.872.121.980.600.121.131.12
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.772.442.412.270.600.590.411.75
Price To Earnings Ratio-----0.853.16-
Price To Sales Ratio21.6337.2357.8612.594.360.431.5558.22
Gross Margin80.3181.2476.5984.9378.8174.9682.6373.01
Operating Margin-694.37-186.13-749.85-922.86-1,558.58-1,329.55-32.78-2,490.59
Net Margin-701.56-183.48-747.45-931.66-1,689.24-1,304.660.98-2,776.92
Shares Outstanding100.9096.1194.3290.9125.157.965.795.70
Market Capitalization329.83440.47375.50349.7576.7811.0041.05125.41

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments253.80102.06114.47122.0081.7978.97126.188.1376.79
Short Term Receivables0.571.710.561.150.750.922.000.001.61
Inventories4.482.820.000.000.000.000.000.000.00
Other Current Assets2.525.597.055.525.343.421.101.211.13
Total Current Assets261.38112.17122.08128.6887.8883.31129.289.3479.53
Net Property, Plant & Equipment1.594.846.398.3310.229.202.360.240.42
Total Investments and Advances0.000.780.781.021.321.731.900.360.35
Intangible Assets26.6027.3517.3517.3517.3527.1127.110.000.00
Other Assets0.891.300.650.200.401.530.050.000.95
Total Assets290.46146.45147.26155.59117.18122.87160.709.9481.25
Short Term Debt Incl. Current Port. of LT Debt0.991.251.102.511.870.790.901.692.31
Accounts Payable5.708.628.957.784.283.142.092.971.89
Other Current Liabilities19.0723.0012.8212.037.878.026.463.256.47
Total Current Liabilities25.7632.8822.8622.3214.0211.959.457.9110.68
Long Term Debt76.2976.8357.1835.9137.9137.6622.028.149.92
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities2.1214.5916.1123.300.830.460.025.571.95
Total Liabilities104.17124.3096.1681.5352.7650.0731.4821.6222.55
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.0065.410.00
Common Equity186.2922.1551.1074.0564.4172.80129.22-77.0958.71
Total Shareholders Equity186.2922.1551.1074.0564.4172.80129.22-11.6858.71
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity186.2922.1551.1074.0564.4172.80129.22-11.6858.71
Total Liabilities & Stockholders Equity290.46146.45147.26155.59117.18122.87160.709.9481.25
Book Value Per Share2.053.899.1618.2668.70133.94240.35-39,458.074,435.56
Tangible Book Value Per Share1.76-0.916.0513.9850.1984.06189.93-39,458.074,435.56
Full-Time Employees45143937083725815-
Price to Book Ratio2.355.662.041.101.001.441.340.26-0.38
Return on Assets-36.25-25.50-66.81-68.83-73.90-43.82-53.69-73.00-76.25
Return on Equity-75.99-102.26-161.67-135.58-129.28-61.51-70.03-141.55-161.38
Return on Invested Capital-30.16-37.83-93.43-85.37-86.68-56.25-34.92--49.36
Quick Ratio9.973.335.345.766.276.9713.681.187.45
Current Ratio10.153.415.345.766.276.9713.681.187.45

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-81.84-79.20-37.45-101.17-93.87-88.70-62.13-52.81-33.28
Depreciation1.771.280.802.001.991.891.230.670.10
Other Funds (Non Cash)13.82-5.12-96.922.319.0417.406.157.324.63
Funds from Operations-66.24-83.04-133.58-96.86-82.84-69.41-54.76-44.82-28.55
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-9.86-2.582.670.345.74-1.50-4.06-3.243.13
Cash from Operating Activities-76.10-85.62-130.90-96.51-77.10-70.91-58.82-48.05-25.42
Capital Expenditures-5.00-3.00-7.33-0.06-0.10-0.61-1.36-0.170.00
Net Assets From Acquisitions0.000.000.000.000.000.000.0026.410.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.000.000.000.00
Purchase or Sale of Investments51.1011.15-30.68-14.820.000.000.000.000.00
Purchase of Investments-1.90-63.39-57.13-16.820.000.000.000.000.00
Sale Or Maturity of Investments53.0074.5426.452.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.00105.000.000.000.000.001.000.00
Cash from Investing Activities46.108.1566.99-14.88-0.10-0.61-1.3627.230.00
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock146.17238.630.2968.08118.0474.250.28140.183.34
Repurchase of Common Pref Stock0.000.000.000.000.00-2.000.000.00-1.13
Sale of Common Pref Stock146.17238.630.2968.08118.0476.250.28140.184.47
Proceedsfrom Stock Options146.07238.530.0059.37117.8375.98-0.28139.394.46
Issuance or Reduction of Debt, Net0.000.0020.0020.44-0.800.0012.390.483.53
Change in Long Term Debt0.000.0020.0020.44-0.800.0012.390.483.53
Issuance of Long Term Debt0.000.0020.0022.500.000.0012.399.859.91
Reduction of Long Term Debt0.000.000.00-2.06-0.800.000.00-9.37-6.38
Net Financing Active Other Cash Flow-0.110.000.000.00-0.010.00-0.280.000.00
Other Financing Activities Uses-0.110.000.000.00-0.010.00-0.280.000.00
Cash from Financing Activities146.06238.6320.2988.52117.2374.2512.39140.666.87
Exchange Rate Effect-0.020.21-0.160.10-0.10-0.320.40-0.250.00
Net Change in Cash116.04161.38-43.77-22.7839.922.41-47.38119.59-18.55
Free Cash Flow--85.62-131.23-96.57-77.20-71.52-60.18-48.23-25.42
Preferred Dividends (Cash Flow)-0.000.000.00--0.00-0.00
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments188.38208.55233.72253.80122.4262.95
Short Term Receivables1.472.051.110.571.611.86
Inventories5.515.504.644.484.083.17
Other Current Assets2.782.762.512.524.704.96
Total Current Assets198.13218.85241.98261.38132.8172.94
Net Property, Plant & Equipment0.320.771.181.591.992.90
Total Investments and Advances0.100.100.000.000.580.80
Intangible Assets30.1830.4526.4126.6026.7926.98
Other Assets3.092.900.700.891.391.55
Total Assets231.82253.06270.28290.46163.56105.17
Short Term Debt Incl. Current Port. of LT Debt0.190.470.730.991.201.37
Accounts Payable4.883.935.075.705.057.71
Other Current Liabilities9.9114.9717.9619.0717.2513.82
Total Current Liabilities14.9819.3723.7725.7623.5122.90
Long Term Debt77.0176.7676.5276.2976.1676.66
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities0.941.481.542.122.271.65
Total Liabilities92.9397.61101.83104.17101.94101.20
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity138.88155.45168.45186.2961.623.97
Total Shareholders Equity138.88155.45168.45186.2961.623.97
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity138.88155.45168.45186.2961.623.97
Total Liabilities & Stockholders Equity231.82253.06270.28290.46163.56105.17
Book Value Per Share1.381.621.792.052.450.50
Tangible Book Value Per Share1.081.301.511.761.39-2.89
Full-Time Employees---45--
Price to Book Ratio2.352.612.021.636.860.48
Return on Assets-40.73-50.32-49.82-36.25-55.66-64.59
Return on Equity-80.32-113.08-104.21-75.99-156.87-207.22
Return on Invested Capital-9.36-6.96-8.26-9.11-21.64-31.93
Quick Ratio12.8611.029.989.975.483.05
Current Ratio13.2211.3010.1810.155.653.19

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-76.794.08-40.4831.35-59.63-51.20
Depreciation0.331.000.220.220.220.35
Other Funds (Non Cash)60.49-17.1223.07-52.6232.1925.15
Funds from Operations-15.97-12.04-17.19-21.05-27.22-25.69
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-4.21-8.75-2.415.52-0.61-4.21
Cash from Operating Activities-20.19-20.79-19.60-15.53-27.82-29.90
Capital Expenditures0.00-5.000.000.000.000.00
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.000.000.00
Purchase or Sale of Investments11.004.0019.2516.85-28.6723.11
Purchase of Investments0.000.000.00-1.90-44.53-5.07
Sale Or Maturity of Investments11.004.0019.2518.7515.8728.18
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities11.00-1.0019.2516.85-28.6723.11
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock0.000.080.00146.0986.915.63
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock0.000.080.00146.0986.915.63
Proceedsfrom Stock Options0.000.080.00145.9986.915.63
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow-0.110.000.000.000.000.00
Other Financing Activities Uses-0.110.000.000.000.000.00
Cash from Financing Activities-0.110.070.00146.0986.915.63
Exchange Rate Effect0.01-0.01-0.020.00-0.000.14
Net Change in Cash-9.29-21.72-0.36147.4230.41-1.02
Free Cash Flow-20.19---15.53-27.82-29.90

Revenue breakdown

License and Other2025: 28.59M
Product2024: 2.56M 2025: 6.52M
United States2024: 2.56M 2025: 35.11M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3010.31%8.0M77.3M851.92K
2026-10-159.98%7.5M75.1M827.27K
2026-09-3010.11%7.6M75.1M840.83K
2026-09-1510.45%8.2M78.9M886.53K
2026-08-319.13%7.2M78.8M764.12K
2026-08-149.09%7.2M78.8M733.98K
2026-07-319.15%7.3M79.8M662.04K
2026-07-158.56%6.5M75.9M627.21K
2026-06-307.25%5.5M75.9M583.29K
2026-06-155.51%4.2M75.9M401.35K
2026-05-294.44%3.4M75.9M431.38K
2026-05-153.85%2.9M75.9M469.17K
2026-04-304.25%3.1M73.4M498.78K
2026-04-154.44%3.1M70.8M479.86K
2026-03-314.45%3.1M70.1M481.20K
2026-03-134.99%3.5M70.1M589.07K
2026-02-275.13%3.5M67.4M607.23K
2026-02-135.01%3.4M67.4M587.42K
2026-01-303.99%3.1M78.3M600.42K
2026-01-153.95%3.1M78.3M1.01M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.001.752.852.3415.5450.006.000.966-0.0110.000
call2.500.003.600.0019.2580.000.000.882-0.0090.001
call4.000.002.950.0020.7850.000.000.940-0.0710.001
call5.000.002.950.103.16345.000.000.261-0.0290.002
call6.000.002.950.003.8460.000.000.231-0.0330.002
call7.500.002.950.004.6080.000.000.207-0.0380.001
put1.000.002.950.005.3380.000.00-0.034-0.0110.000
put2.500.000.050.107.60561.000.00-0.207-0.0610.001
put4.000.003.600.0020.5210.000.00-0.060-0.0700.001
put5.000.304.600.0021.2100.000.00-0.739-0.0290.002
put6.000.505.000.0015.4200.000.00-0.769-0.0330.002
put7.502.006.500.0016.1630.000.00-0.793-0.0370.001

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-10-298-KCurrent report2026-10-29SEC
2026-10-194Statement of changes in beneficial ownership of securities2026-10-16SEC
2026-10-088-KCurrent report2026-10-07SEC
2026-10-07SCHEDULE 13G/ASEC
2026-10-054Statement of changes in beneficial ownership of securities2026-10-01SEC
2026-10-01144Filing for proposed sale of securities under Rule 144.SEC
2026-09-21SCHEDULE 13GSEC
2026-09-098-KCurrent report2026-09-08SEC
2026-09-088-KCurrent report2026-09-08SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-134Statement of changes in beneficial ownership of securities2026-08-12SEC
2026-08-13144Filing for proposed sale of securities under Rule 144.SEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-07-30SCHEDULE 13GSEC
2026-07-014Statement of changes in beneficial ownership of securities2026-06-30SEC
2026-07-014Statement of changes in beneficial ownership of securities2026-07-01SEC
2026-07-013Initial statement of beneficial ownership of securities2026-07-01SEC
2026-07-018-KCurrent report2026-06-30SEC
2026-05-15SCHEDULE 13G/ASEC
2026-05-14EFFECTEffectiveness filing by commission orderSEC
2026-05-138-K/A2026-05-11SEC
2026-05-134Statement of changes in beneficial ownership of securities2026-05-12SEC
2026-05-128-KCurrent report2026-05-11SEC
2026-05-12CORRESPSEC
2026-05-12144Filing for proposed sale of securities under Rule 144.SEC
2026-05-11UPLOADUpload SubmissionSEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-1011.88K133.66K1
2026-090000
2026-0800320.06K2
2026-070000
2026-060036.43K1
2026-050072.82K1
2026-040000
2026-030000
2026-020000
2026-010000
2025-120000
2025-110000

Institutional holders

Manager% owned
MORGAN STANLEY10.03%
Bain Capital Life Sciences Investors, LLC8.45%
PERCEPTIVE ADVISORS LLC8.41%
Kalehua Capital Management LLC7.89%
Saturn V Capital Management LP7.39%
Empery Asset Management, LP7.35%
Deep Track Capital, LP6.23%
BlackRock, Inc.5.89%
FMR LLC5.54%
Nantahala Capital Management, LLC5.19%

Funds

Fund% owned
Fidelity Small Cap Growth Fund3.59%
VANGUARD TOTAL STOCK MARKET INDEX FUND2.76%
Inception Portfolio2.45%
iShares Russell 2000 ETF2.02%
EQ/Morgan Stanley Small Cap Growth Portfolio1.93%
Fidelity Small Cap Growth K6 Fund1.79%
Select Biotechnology Portfolio1.44%
Fidelity Advisor Biotechnology Fund1.42%
VANGUARD EXTENDED MARKET INDEX FUND1.09%
Fidelity Small Cap Index Fund0.94%

OakChart. XFOR. Cached 15 minutes.